Cambridge, MA, United States of America

Daniel Tavares

This inventor holds 1 USPTO granted patent and 1 published patent application, plus 4 CIPO patents. Top assignee: Millennium Pharmaceuticals Limited. Active years: 2024.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Daniel Tavares

Introduction

Daniel Tavares is an accomplished inventor based in Cambridge, MA. He is known for his significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. His work has the potential to impact the treatment of various B-cell disorders.

Latest Patents

Daniel Tavares holds a patent for "Anti-CD19 antibodies and uses thereof." This patent describes antibodies, fragments thereof, and fusion proteins that specifically bind to CD19. The methods of making and using such antibodies are also detailed in the patent. These innovations are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. He has 1 patent to his name.

Career Highlights

Tavares is currently employed at Millennium Pharmaceuticals Limited, where he continues to advance his research in antibody development. His work at this leading biotechnology company has positioned him at the forefront of medical innovation.

Collaborations

Daniel collaborates with talented professionals in his field, including Bianka Prinz and James Geoghegan. Their combined expertise contributes to the success of their projects and the advancement of therapeutic solutions.

Conclusion

Daniel Tavares is a notable inventor whose work in antibody technology holds promise for the treatment of serious medical conditions. His contributions to the field exemplify the impact of innovation in biotechnology.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…